Dr Sam Whitmarsh

Director of Analytical Science and Digital Transformation

Sam obtained an MChem from the University of Southampton in 2003 with an industrial placement at Merck GmbH. He was awarded his PhD from the University of Bristol following his work with Prof Anthony Davis on the synthesis of novel steroid macrocycles and measurement of their complexes by high resolution mass spectrometry. In 2007, Sam joined Process R&D in AstraZeneca as an Analytical Scientist, leading analytical components of drug development across pre-clinical to Phase III drug candidate projects. In this role he also worked on analytical method QBD, trace genotoxic impurities and novel approaches to high throughput chromatographic analysis. In 2010, Sam moved to BP and carried out a range of technical and people leadership roles over the next 10 years. He led the formation of the high-resolution mass spectrometry petroleomics facility in the UK, managed a team of 35 staff and left BP as Global Analytical Expert, leading the BP Analytical Science Network. Sam is also a Fellow of the Royal Society of Chemistry (RSC) sitting on the RSC Separation Science interest group, Chemical Information and Computer Applications Group and the Society of Chemical Industry (SCI) Data, Digital and AI committee.

Sam joined CatSci Ltd in 2020 as Head of Process R&D, and in 2023 he became Director of Analytical Science and Digital Transformation. In 2023, CatSci expanded their offerings with the launch of their GMP Analytical Science capability, opening state-of-the-art laboratories in Dagenham dedicated to analytical excellence. Sam was instrumental in the implementation of this offering. He is committed to leveraging his extensive analytical experience to address some of the key analytical challenges affecting customers worldwide in order to deliver medicines to patients in need. Sam has a passion for building culture, solutions and tools that revolutionise how we do science and business at CatSci.

Our team